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Abstract
Fluoroquinolones (FQ) form the backbone in experimental treatment regimens against drug-susceptible tuberculosis.
However, little is known on whether the genetic variation present in natural populations of Mycobacterium tuberculosis
(Mtb) affects the evolution of FQ-resistance (FQ-R). To investigate this question, we used nine genetically distinct drug-
susceptible clinical isolates of Mtb and measured their frequency of resistance to the FQ ofloxacin (OFX) in vitro. We
found that theMtb genetic background led to differences in the frequency of OFX-resistance (OFX-R) that spanned two
orders of magnitude and substantially modulated the observed mutational profiles for OFX-R. Further, in vitro assays
showed that the genetic background also influenced the minimum inhibitory concentration and the fitness effect
conferred by a given OFX-R mutation. To test the clinical relevance of our in vitro work, we surveyed the mutational
profile for FQ-R in publicly available genomic sequences from clinical Mtb isolates, and found substantial Mtb lineage-
dependent variability. Comparison of the clinical and the in vitro mutational profiles for FQ-R showed that 51% and 39%
of the variability in the clinical frequency of FQ-R gyrA mutation events in Lineage 2 and Lineage 4 strains, respectively,
can be attributed to howMtb evolves FQ-R in vitro. As theMtb genetic background strongly influenced the evolution of
FQ-R in vitro, we conclude that the genetic background of Mtb also impacts the evolution of FQ-R in the clinic.
Key words: Mycobacterium tuberculosis, antimicrobial resistance, evolution, fluoroquinolones, epistasis,
mycobacteria, fitness.
Introduction
Antimicrobial resistance (AMR) poses a major threat to our
ability to treat infectious diseases (MacGowan 2008; Winston
and Mitruka 2012). The rise of AMR is a complex phenom-
enon with a broad range of contributing socioeconomic and
behavioral factors (Dalton et al. 2012; Merker et al. 2015;
Alvarez-Uria et al. 2016; Eldholm et al. 2016; Shah et al.
2017). However, the emergence of AMR within any pathogen
population is ultimately an evolutionary process (zur Wiesch
et al. 2011; Hughes and Andersson 2017). This evolutionary
process is influenced by multiple factors, including drug pres-
sure and pathogen genetics. Firstly, the drug type and drug
concentration can affect the nature and relative frequencies
of AMR mutations observed in a given pathogen population
(also known as the mutational profile for AMR) (Zhou et al.
2000; Ford et al. 2013; Lindsey et al. 2013; McGrath et al. 2014;
Hughes and Andersson 2017; Huseby et al. 2017). Secondly,
pathogen populations comprise genetically distinct strains,
and this genetic variation may also influence AMR evolution
(Fenner et al. 2012; Vogwill et al. 2014, 2016; Gagneux 2018).
Different pathogen genetic backgrounds can have different
baseline susceptibilities to a given drug (€Angeby et al. 2010;
Coeck et al. 2016), which can consequently affect patient
treatment outcomes (Colangeli et al. 2018). The genetic
background has also been shown to modulate the acquisition
and prevalence of AMR (Borrell and Gagneux 2009; Fenner
et al. 2012; Ford et al. 2013; Wollenberg et al. 2017), the mu-
tational profile for AMR (Fenner et al. 2012; Ford et al. 2013;
Vogwill et al. 2014; Oppong et al. 2019), and the phenotypic
effects of AMR mutations (Gagneux et al. 2006; Decuypere
et al. 2012; Angst and Hall 2013; Vogwill et al. 2016). Studying
the interplay between pathogen genetics and drug pressure is
therefore important in understanding how to restrict the
emergence of AMR in pathogen populations.
AMR in Mycobacterium tuberculosis (Mtb), the etiological
agent of human tuberculosis (TB), is of particular importance.
Mtb infections globally cause the highest rate of mortality due
to a single infectious agent both in general, and due to AMR
specifically (World Health Organization 2017). Although the
genetic variation in Mtb is small compared with other bacte-
rial pathogens (Comas et al. 2010; Gagneux 2018), several
studies have shown that this limited genetic variation influ-
ences AMR phenotypes and prevalence (Gagneux et al. 2006;
Zaczek et al. 2009; Fenner et al. 2012; Gagneux 2018). The
global genetic diversity of Mtb comprises seven phylogenetic
lineages (Comas et al. 2010; Gagneux 2018), and Mtb strains
belonging to the Lineage 2 Beijing/W genetic background
have repeatedly been associated with multidrug-resistant
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TB (MDR-TB; defined as an infection from an Mtb strain that
is resistant to at least isoniazid and rifampicin) both in vitro
and in clinical settings (Borrell and Gagneux 2009; Fenner
et al. 2012; Ford et al. 2013; Merker et al. 2015; Wollenberg
et al. 2017).
One strategy to reduce the emergence of AMR in Mtb is
the development of new, shorter treatment regimens
(Imperial et al. 2018; Vjecha et al. 2018). Many such experi-
mental regimens use third- or fourth-generation fluoroquino-
lones (FQ) against drug-susceptible Mtb (Gillespie et al. 2014;
Jindani et al. 2014; Merle et al. 2014; Imperial et al. 2018;
Vjecha et al. 2018). However, FQs have long been integral
to treating MDR-TB (Takiff and Guerrero 2011), and the pre-
vious use of FQs has led to the emergence of FQ-resistance
(FQ-R) in clinical strains of Mtb (Takiff et al. 1994; Maruri et al.
2012; Shah et al. 2017). FQ-R is one of the defining properties
of extensively drug-resistant TB (XDR-TB), and XDR-TB
accounts for 8.5% of MDR-TB cases (World Health
Organization 2017). Understanding how FQ-R is acquired in
natural populations of Mtb may allow for the development of
tools or strategies to mitigate further increases in FQ-R
prevalence.
In Mtb, the sole target of FQ is DNA gyrase (Takiff et al.
1994; Zhou et al. 2000; Piton et al. 2010; Aldred et al. 2016;
Blower et al. 2016). Consequently, clinically relevant FQ-R in
Mtb is primarily due to a limited set of chromosomal muta-
tions located within the “quinolone-resistance-determining
region” (QRDR) of the gyrA and gyrB genes, which encode
DNA gyrase (Takiff et al. 1994; Maruri et al. 2012; Wollenberg
et al. 2017). No horizontal gene-transfer or plasmid-based
resistance to FQ has been documented in Mtb (Boritsch
et al. 2016; Gygli et al. 2017). Studying FQ-R evolution in
Mtb populations thus provides a promising setting for eluci-
dating how the genetic background may affect the emer-
gence and maintenance of clinically relevant chromosomal
AMR mutations in bacterial populations.
While a great deal of literature exists on the biochemical
mechanisms leading to the FQ-R phenotype in Mtb (Zhou
et al. 2000; Piton et al. 2010; Mustaev et al. 2014; Aldred et al.
2016; Blower et al. 2016), little is known on the evolutionary
dynamics of FQ-R in different populations of Mtb. Given that
antimicrobial regimens against Mtb infections use standard-
ized, empirical dosing strategies (World Health Organization
2017), it is unclear whether different Mtb genetic back-
grounds would acquire FQ-R at the same frequency when
exposed to the same antimicrobial concentration. Whether
the Mtb genetic background would also modulate the mu-
tational profile for FQ-R, or the phenotypic effects of FQ-R
mutations, is unknown. Such knowledge may provide insights
on how to maintain or prolong the efficiency of FQs against
different genetic variants of Mtb in the clinic.
In this study, we tested whether the Mtb genetic back-
ground plays a role in the evolution of FQ-R. We showed that
the Mtb genetic background can lead to differences in the
frequency of FQ-R emergence that span two orders of mag-
nitude, as well as substantially modulate the mutational pro-
file for FQ-R. We further demonstrated that the phenotypic
effects of clinically relevant FQ-R mutations differed
depending on the Mtb genetic background they were present
in. Analysis of publicly available genomic sequences from clin-
ical Mtb isolates also revealed a positive association between
the FQ-R mutational profiles observed in vitro and the mu-
tational profiles observed in the clinic. Taken together, we
showed that the Mtb genetic background had a considerable
role in evolution of FQ-R in the clinic.
Results
Frequency of Ofloxacin-Resistance in Mtb Is Strain-
Dependent
We first tested for whether the Mtb genetic background led
to differences in the frequency of FQ-R acquisition. To do so,
we performed a Luria–Delbru¨ck fluctuation analysis on nine
drug-susceptible and genetically distinct Mtb clinical strains
belonging to Lineage 1 (L1), Lineage 2 (L2), and Lineage 4 (L4)
(supplementary table S1, Supplementary Material online)
(Luria and Delbru¨ck 1943; Comas et al. 2010; Gagneux 2018;
Borrell et al. 2019). We measured their frequency of resistance
in vitro to the FQ ofloxacin (OFX), as OFX was used exten-
sively to treat MDR-TB patients in the past (Takiff and
Guerrero 2011). Given that anti-TB treatment regimens use
standardized drug concentrations (World Health
Organization 2017), we also measured the frequency of resis-
tance to the same concentration of OFX (4mg/ml) for all nine
strains. We observed significant strain-dependent variation in
the frequency of OFX-resistance (OFX-R) at 4mg/ml, with the
difference spanning two orders of magnitude (fig. 1A;
P¼ 2.2 1016, Kruskal–Wallis). Several of the nine drug-
susceptible Mtb strains contained missense substitutions in
DNA gyrase that are not associated with FQ-R (supplemen-
tary table S2, Supplementary Material online) (Borrell et al.
2019). These mutations are phylogenetic markers that reflect
the population structure of Mtb and cannot be avoided if
strains from different Mtb lineages are used (Comas et al.
2010; Gagneux 2018). We found no evidence for any associ-
ations between the presence a given phylogenetic DNA gyr-
ase missense mutation and the frequency of OFX-R acquired.
The concentration of the antimicrobial can affect the ob-
served frequencies of AMR in Mtb (Zhou et al. 2000; Ford
et al. 2013; McGrath et al. 2014). Therefore, we tested whether
changing the selective concentration of OFX would affect the
relative differences in strain-specific OFX-R frequencies. For
the sake of simplicity, we tested only two strains, with each
strain at the opposite extremes of the frequency of resistance
to 4mg/ml OFX, as shown in figure 1A: N0157 (high OFX-R
frequency) and N0145 (low OFX-R frequency). We found that
the frequency of OFX-R remained one to two orders of mag-
nitude higher in N0157 than in N0145 across all the concen-
trations we tested (fig. 1B, P¼ 2.46105 for 2mg/ml OFX,
and P¼ 4.03106 for 8mg/ml OFX, Wilcoxon rank-sum
test). The N0157 strain had nearly confluent growth at
2mg/ml OFX, which is the OFX concentration that has
been shown to inhibit 95% of Mtb strains that have not
been previously exposed to OFX, but does not inhibit Mtb
strains that are considered resistant to OFX in the clinic
(€Angeby et al. 2010; Coeck et al. 2016). This suggested that
Castro et al. . doi:10.1093/molbev/msz214 MBE
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N0157 has low-level resistance to OFX, despite having no
mutation in the QRDR. Meanwhile, at 8mg/ml OFX, we ob-
served only four resistant colonies for N0145 across all sam-
ples, with all colonies arising within the same culture.
The variation in OFX-R frequencies when selecting on the
same concentration of OFX may be driven by several, non-
exclusive biological factors. Firstly, the Mtb strains we tested
may have different baseline DNA mutation rates. Secondly,
the number and relative frequency of potential mutations
that confer OFX-R may vary depending on the Mtb ge-
netic background. Thirdly, the relative cost of OFX-R
mutations may differ between Mtb genetic backgrounds.
As the observed frequency of OFX-R in Mtb is likely the
result from a combination of multiple factors, we took
advantage of the fact that we had identified strains with a
range of OFX-R frequencies. We selected three represen-
tative strains with significantly different OFX-R frequen-
cies: N0157, N1283, and N0145. These strains had a high-,
mid-, and low frequency of OFX-R, respectively (fig. 1A).
We then explored the relative contributions of each bio-
logical factor listed above in driving the variation in OFX-
R across genetically distinct Mtb strains.
Mutation Rate Differences Do Not Drive the In Vitro
Variation in OFX-R Frequency in Mtb
We first tested for the presence of differential mutation rates
between our panel of Mtb strains in figure 1A. Mutations in
dnaE, which encodes the replicative DNA polymerase and
serves as the major replicative exonuclease in Mtb, have
been shown to confer a hypermutator phenotype in Mtb in
the absence of environmental stress (Rock et al. 2015; Ba~nos-
Mateos et al. 2017). While dnaE mutations were present in
the genomic data of our panel of drug-susceptible Mtb strains
(supplementary table S2, Supplementary Material online)
(Borrell et al. 2019), none was in the polymerase and histidinol
phosphatase domain of DnaE, the region where mutations
would impart a hypermutator phenotype (Rock et al. 2015;
Ba~nos-Mateos et al. 2017). We did not test for the presence of
dnaE mutations in the resistant colonies following the fluc-
tuation analysis, as we reasoned that the likelihood of gaining
both a dnaE and a gyrA double mutation within this relatively
short period is extremely low as to be considered negligible.
To test for mutation rate variation in vitro, we again con-
ducted a fluctuation analysis on N0157, N1283, and N0145
(the high-, mid-, and low-frequency OFX-R strains,
A B
FIG. 1. Variation in the frequency of ofloxacin-resistance between genetically distinct, wild-type Mycobacterium tuberculosis strains. (A) Frequency
of ofloxacin-resistance at 4 mg/ml ofloxacin (OFX), as measured by fluctuation analysis. Top panel: colored points represent the frequency of
ofloxacin-resistance per cell per parallel culture, with darker points representing multiple cultures with the same frequency. Colors denote the
lineage that theMtb strain belongs to (L1, pink; L2, blue; L4, red). Gray points represent the estimated number of drug-resistance mutations per cell
per strain as calculated by MSS-MLE, while black bars denote the respective 95% confidence intervals. Bottom panel: the percentage of parallel
cultures lacking OFX-resistant mutants. (B) Frequency of ofloxacin-resistance at 2 or 8mg/ml OFX. ††Due to restrictions on the range of values that
the MSS-MLE method is valid for (see Materials and Methods), the estimated number of drug-resistance mutations per cell for N0157 at 2 mg/ml
OFX, as presented here, is an underestimate.
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respectively), but used streptomycin (STR; 100mg/ml) instead
of OFX. We hypothesized that if the frequency of OFX-R is
driven by differential mutation rates, then we should expect
similar differences in the frequency of STR-resistance (STR-R).
However, we observed no evidence for differences in the fre-
quency of STR-R between the strains tested (fig. 2, P¼ 0.135,
Kruskal–Wallis; supplementary table S3, Supplementary
Material online). This suggested that the observed differences
in frequency of resistance are specific to OFX, and that there
are limited, if any, inherent differences in mutation rates be-
tween the Mtb strains tested.
Mutational Profile for OFX-R Is Highly Strain-
Dependent
We next determined the mutational profile for OFX-R for
each strain used in the fluctuation analysis at 4mg/ml OFX
(fig. 1A). The QRDR mutations in 680 gyrA and 590 gyrB
sequences were identified in the resistant colonies. We ob-
served that gyrA mutations made up 99.7% of the QRDR
mutations observed (645 gyrA mutations, 2 gyrB mutations),
and no QRDR double mutants were present (supplementary
fig. S1 and tables S4 and S5, Supplementary Material online).
The mutational profiles for OFX-R were also highly strain-
specific (fig. 3A, P¼ 5.00 104, Fisher’s exact test).
Specifically, the GyrA A90V mutation was most prevalent
in the high-frequency OFX-R strains, while GyrA D94G was
most prevalent in all other strains. There was also a slight
trend showing that strains with a greater number of unique
gyrA mutations present also had higher rates of OFX-R
(figs. 1A and 3B).
The strain-dependent variation in the mutational profile
for OFX-R may be due to gyrA mutations conferring different
FIG. 2. The frequency of streptomycin-resistance at 100 mg/ml strep-
tomycin (STR) for wild-type N0157, N1283, and N0145
Mycobacterium tuberculosis strains, as measured by fluctuation anal-
ysis. Top panel: colored points represent the frequency of streptomy-
cin-resistance per cell per parallel culture, with darker points
representing multiple cultures with the same frequency. Colors de-
note the lineage that the Mtb strain belongs to (L1, pink; L2, blue; L4,
red). Gray points represent the estimated number of drug-resistance
mutations per cell per strain as calculated by MSS-MLE, while black
bars denote the respective 95% confidence intervals. Bottom panel:
the percentage of parallel cultures lacking STR-resistant mutants.
Two biological replicates are presented for each Mtb strain, with
each replicate identifier suffixed after the strain name.
A
B
FIG. 3. Variation in the mutational profile for ofloxacin-resistance
after fluctuation analyses using nine genetically distinct
Mycobacterium tuberculosis strains. (A) Mutations in the quino-
lone-resistance-determining region (QRDR) of gyrA were analyzed
in 680 ofloxacin (OFX)-resistant colonies from the fluctuation anal-
ysis performed in figure 2A (nm, no identified QRDR gyrAmutations).
Strains are ordered left to right based on their frequency of OFX-
resistance at 4 mg/ml OFX. Numbers of colonies analyzed per strain
are reported directly above each column. (B) The number of unique
QRDR gyrA mutations per Mtb strain for OFX-resistance. Bar colors
denote the Mtb lineage the strain belongs to (L1, pink; L2, blue; L4,
red).
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resistance levels depending on the Mtb strain they are present
in. To test this hypothesis, we first isolated OFX-R mutants
carrying one of four possible GyrA mutations (G88C, A90V,
D94G, or D94N) in the three strains used in figure 2: N0157,
N1283, and N0145. The OFX MIC was determined for each of
the 12 OFX-R mutant strains, along with their respective wild-
type ancestors. We found that each parental wild-type strain
had different susceptibilities to OFX, with N0157, N1283, and
N0145 having OFX MICs of 2, 0.6, and 0.5mg/ml, respectively
(fig. 4A and supplementary table S6, Supplementary Material
online). This was consistent with the fluctuation analysis
results shown in figure 1B. Furthermore, we observed that
the OFX MIC conferred by a given gyrA mutation varied
depending on the strain it was present in (fig. 4B and
supplementary table S6, Supplementary Material online).
For example, mutants in the N0157 strain generally had
higher OFX MICs than mutants in either the N0145 or
N1283 strains. The only mutation that deviated from this
trend was GyrA G88C, which conferred a higher OFX MIC
when in the N0145 strain. Notably, the GyrA A90V mu-
tation conferred a resistance level 4 mg/ml OFX in the
N0157 and N1283 strains, but not in N0145. This was
consistent with the presence of GyrA A90V in the OFX-
R mutational profile for N0157 and N1283, but not in
N0145, in the fluctuation analysis using 4 mg/ml OFX
(figs. 1A and 3). In summary, the differences in OFX
MIC reflected the strain-dependent mutational profiles
for OFX-R in Mtb, as expected.
Fitness of OFX-R Mutations Are Associated with Their
Relative Frequency In Vitro
While the OFX MICs may determine which mutations may
be observed in a fluctuation analysis, it is not the sole param-
eter to influence the OFX-R mutational profile for a given
strain. We found that while the same gyrA mutation can be
observed in two different Mtb strains, their relative frequen-
cies may vary (fig. 3). This variation may be due to the fitness
of a given gyrA mutant being different across genetic back-
grounds. To test this hypothesis, we used cell growth assays in
antibiotic-free conditions to measure the in vitro fitness of
our panel of OFX-R mutants relative to their respective pa-
rental wild-type ancestors. We observed that the relative fit-
ness of the OFX-R mutants was modulated by both the gyrA
mutation and the Mtb strain they were present in (fig. 5A;
supplementary figs. S2 and S3 and table S7, Supplementary
Material online). Furthermore, there was a positive associa-
tion between the fitness of a given gyrA mutation with its
relative frequency in the fluctuation analysis for the N0157
and N1283 strains (fig. 5B, P¼ 0.03 for N0157, P¼ 0.05 for
N1283). There was no evidence of an association in the N0145
background due to the lack of GyrA G88C and A90V mutants
in its fluctuation analysis.
The results from figures 4 and 5, as well as the apparent
lack of mutation rate differences between our strains (fig. 2),
suggested that differential mutational profiles were an impor-
tant contributor in the variation in OFX-R frequency in Mtb.
These mutational profile differences appear to be driven by
the Mtb genetic background’s effect on both the MIC and the
relative fitness cost of OFX-R mutations. We next explored
whether these in vitro results would be relevant in clinical
settings.
Mutational Profile for FQ-R In Vitro Reflects Clinical
Observations
To explore the clinical relevance of our in vitro work, we
surveyed the FQ-R mutational profile from publicly available
Mtb genomes obtained from clinical isolates. FQs are gener-
ally used for treatment against MDR-TB (World Health
Organization 2017). While it is unclear whether resistance
mutations for isoniazid (INH) and/or rifampicin (RIF)
A B
FIG. 4. The Mycobacterium tuberculosis genetic background modu-
lates the ofloxacin (OFX) minimum inhibitory concentration (MIC).
(A) Heat-map of OFX-susceptibility via Alamar Blue assay for gyrA
mutant strains of Mtb, as well as their wild-type ancestor, in three
genetic backgrounds (N0157, N0145, or N1283). Light areas represent
growing cultures, while dark areas represent nongrowing cultures.
Yellow points represent estimates for OFX MIC (95% reduction
in fluorescence). Areas of solid black colors (at 16þ lg/ml OFX for
wild-type) and solid light beige colors (at <0.125 lg/ml OFX for
mutants) were not measured and colored in for illustrative purposes.
(B) OFX MIC estimates for each strain per genetic background, super-
imposed. Colored points and lines represent MIC measurements for
highlighted genetic background, with the line color denoting the
lineage that the strain belongs to (L1, pink, L2, blue, L4, red). Gray
points and lines represent the other two genetic backgrounds. Solid
horizontal black line denotes 4 lg/ml OFX, while dashed horizontal
black line denotes 1 lg/ml OFX.
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predispose a strain to become FQ-R, the prevalence of FQ-R is
heavily biased toward MDR-TB strains due to treatment prac-
tices. We therefore based our analyses on a collated data set
of 3,450 publicly available MDR-TB genomes (supplementary
table S8, Supplementary Material online), which we con-
firmed to be MDR-TB based on the presence of known
INH-resistance (INH-R) and RIF-resistance (RIF-R) mutations.
This data set provided a reasonable sampling of the overall
genetic diversity of Mtb, as six of the seven known phyloge-
netic Mtb lineages were represented (Lineages 1–6) (Comas
et al. 2010; Gagneux 2018). We catalogued their FQ-R muta-
tional profiles, and found 950 FQ-R mutations in 854
genomes (supplementary tables S9 and S10, Supplementary
Material online), showing that multiple FQ-R mutations may
be present in the genome of a single Mtb clinical isolate. The
frequency of FQ-R differed between lineages, with the highest
frequencies present in L2 and L4 strains (supplementary table
S9, Supplementary Material online, P< 2.20 1016, Chi-
square Goodness of Fit Test). Moreover, we noticed a
lineage-dependent mutational profile for FQ-R (fig. 6,
P¼ 7.10 105, Fisher’s exact test; supplementary tables
S10 and S11, Supplementary Material online). For example,
while the GyrA D94G mutation was most prevalent in strains
belonging to L1, L2, and Lineage 3 (L3), the GyrA A90V mu-
tation was most prevalent in L4 and Lineage 6 (L6).
We observed that the mutational profile for FQ-R in the
fluctuation analysis experiments mimicked published clinical
data. Firstly, gyrA mutations made up the large majority of
FQ-R mutations in vitro (fig. 3 and supplementary tables S4
and S5, Supplementary Material online) and 944 out of the
950 QRDR mutations in the clinic (99.6%; supplementary
table S10, Supplementary Material online). We then tested
whether the Mtb genetic background had an impact on FQ-R
A B
FIG. 5. The Mycobacterium tuberculosis genetic background modulates the fitness effect of fluoroquinolone-resistance mutations. (A) Fitness of
ofloxacin-resistant Mtb strain with specified gyrA mutation relative to the fitness of their respective wild-type ancestral strain. Fitness was
measured by cell growth assay in antibiotic-free conditions. Ancestral strain per gyrA mutant is indicated in the gray bar above each panel. (B)
Association between the relative fitness of specified gyrAmutant and their absolute frequency after the fluctuation analysis performed in figure 1A
and as reported in figure 3A, in three genetic backgrounds (N0157, N1283, and N0145).
FIG. 6. Mutational profile for fluoroquinolone-resistance gyrA muta-
tions is lineage-specific in clinical isolates of Mycobacterium tubercu-
losis. An initial data set consisting of 3,450 genomes with confirmed
MDR-TB mutations were surveyed. About 854 genomes were iden-
tified as fluoroquinolone-resistant, with 848 of these genomes con-
taining at least one gyrA mutation. Only fixed fluoroquinolone-
resistance mutations in the gyrA gene are enumerated here (n ¼
710). No fixed mutations were observed in Lineage 5 strains.
Numbers of genomes analyzed per lineage are presented directly be-
low their respective bar graph.
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gyrA mutational profiles in the clinic as it did in vitro.
However, transmission events can modulate the frequency
of FQ-R gyrA mutations in the clinic, but not in a fluctuation
analysis. If each genome from the clinical data is treated as an
independent event, then number of FQ-R gyrA mutation
events in the clinic would be overestimated compared with
the number of mutation events in a fluctuation analysis.
Therefore, rather than directly compare the frequency of
gyrA mutations from the OFX-R mutational profile in figure 3
to the absolute frequency of gyrA mutations in the genomic
data survey, we instead compared the in vitro frequency of
gyrA mutations in figure 3 to the frequency of mutation
events per gyrA mutation in the genomic data. To do so,
we first used differences in the number of single-nucleotide
polymorphisms (SNPs) as a measure of genetic distance be-
tween two genomes, then defined transmission clusters
within the 3,450 MDR-TB genomes via a conservative cutoff
of 12 SNPs average distance (Walker et al. 2013). Each unique
and fixed FQ-R gyrA mutation present per transmission clus-
ter, as well as each fixed FQ-R gyrA mutations present in
nonclustered genomes, were counted as independent muta-
tion events. We limited our analysis to L2 and L4 strains, as
these two lineages had the highest clinical frequencies of FQ-
R. We observed that the profile for FQ-R gyrA mutation
events in L2 strains differed significantly to L4 strains (supple-
mentary fig. S5, Supplementary Material online, P¼ 0.02,
Fisher’s exact test; supplementary table S12, Supplementary
Material online). Furthermore, there was a positive associa-
tion between the frequency of a given FQ-R gyrA mutation in
our fluctuation analysis compared with the frequency of its
mutation event in the clinic for both L2 and L4 strains (fig. 7,
P¼ 0.02 for L2, P¼ 0.04 for L4). Based on the adjusted R2
values, 51% of the variability in the clinical frequencies of FQ-R
gyrA mutation events in L2 strains and 39% of the variability
in L4 strains can be attributed to how FQ-R evolves in Mtb
in vitro. As the in vitro evolution of FQ-R is itself modulated
by the Mtb genetic background, this provided evidence for
the Mtb genetic background’s role in the evolution of FQ-R in
the clinic.
Discussion
Overall, we illustrate the Mtb genetic background’s consider-
able role in the evolution of resistance to FQs, a clinically
important antimicrobial. We first explored whether the ge-
netic variation among natural populations of Mtb can influ-
ence FQ-R evolution in vitro. Specifically, considering that
Mtb treatment regimens are based on standardized antimi-
crobial concentrations (World Health Organization 2017), we
tested whether different genetic variants of Mtb would ac-
quire FQ-R at the same frequency when exposed to the same
concentration of FQ. Fluctuation analysis on nine, genetically
distinct, drug-susceptible Mtb strains showed that the genetic
background can have a drastic effect on the rate of OFX-R
acquisition when using the same concentration of OFX
(fig. 1). Our results provide the first evidence showing that
the Mtb genetic background can modulate the frequency of
FQ-R acquisition.
However, the effect of the Mtb genetic background on
AMR frequencies observed here in the context of OFX-R dif-
fered from those reported in previous work focusing on other
antibiotics. Past literature has focused on the positive associ-
ation between MDR-TB and L2 Beijing (Borrell and Gagneux
2009; Fenner et al. 2012; Merker et al. 2015; Eldholm et al.
2016). Initial genetic analysis on a global collection of strains
showed that mutations in DNA repair genes were associated
with being MDR-TB, and that these mutations were specific
to L2 Beijing isolates (Rad et al. 2003). The authors thus hy-
pothesized that L2 Beijing strains may have a hypermutator
phenotype, which would lead to higher rates of AMR muta-
tions acquisition (Rad et al. 2003). Based on this L2 Beijing
hypermutator hypothesis, one would expect that L2 Beijing
strains would also show higher frequencies of FQ-R. However,
this was not the case in our fluctuation analysis for OFX-R, as
one of our L2 Beijing strains (N0145) repeatedly acquired the
lowest frequency of OFX-R (fig. 1). Moreover, we saw minimal,
if any, DNA base-pair mutation rate differences between
three Mtb strains (one of which was L2 Beijing) with different
in vitro OFX-R frequencies (fig. 2). Our results therefore con-
tradict the L2 Beijing hypermutator hypothesis. Published
experimental work have also provided varying results. Initial
fluctuation analyses showed no difference in the frequency of
RIF-R in L2 Beijing strains compared with non-L2 Beijing
strains (Werngren and Hoffner 2003). In contrast, a fluctua-
tion analysis performed by Ford et al. (2013) showed that L2
FIG. 7. Association between the clinical frequency of mutation events
of each fluoroquinolone-resistance (FQ-R) gyrA mutations with their
respective in vitro frequencies among Mycobacterium tuberculosis
strains belonging to either the L2 or L4 lineages. Mutation events
per FQ-R gyrA mutation were enumerated from an initial data set
of 3,450 genomes with confirmed MDR-TB mutations. Each unique
and fixed FQ-R gyrA mutation present per transmission cluster
(cutoff¼12 SNPs average distance), as well as each fixed FQ-R gyrA
mutation present in nonclustered genomes, were counted as inde-
pendent mutation events. The in vitro frequencies of FQ-R gyrA
mutations presented here are the same as in figure 3A, grouped by
lineage.
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Beijing strains had higher frequencies of resistance for INH,
RIF, and ethambutol compared with L4 strains, even after
correcting for differences in AMR mutational profiles. Lastly,
a more recent fluctuation analysis using the same concentra-
tions of INH or RIF as Ford et al. showed that while different
Mtb strains had different frequencies of INH-R, a L2 Beijing
strain did not have higher frequencies of INH-R nor RIF-R
compared with non-L2 Beijing strains (Carey et al. 2018).
Although diverging in their results, these in vitro and genetic
studies, together with the study conducted here, highlight the
importance of the genetic background when testing for the
frequency of AMR in Mtb. Furthermore, these results show
that differential DNA mutation rates is not the only param-
eter relevant in determining the frequency of FQ-R in Mtb.
If DNA mutation rates do not contribute to the variation
in OFX-R frequency, we hypothesized that differences in the
phenotypic effects of OFX-R mutations, and their consequent
effect on the mutational profiles for OFX-R, may be impor-
tant contributors. By sequencing the QRDR from resistant
colonies in our OFX fluctuation analysis, we observed
strain-specific patterns in the mutational profiles for OFX-R
(fig. 3). This suggested that the mutational profile for FQ-R is
not only a function of the FQ type and concentration (Zhou
et al. 2000; Malik et al. 2010, 2016; Huseby et al. 2017) but that
epistatic interactions between a given FQ-R mutation and
the genetic background may also play a role. Similar epis-
tasis between the phenotype of a given AMR mutation
and the genetic background have been observed in other
bacteria. For example, a given RIF-R rpoB mutation can
confer differential MIC and fitness costs depending on the
genetic background it occurred in, or on the presence of
other AMR mutations, in Escherichia coli (Angst and Hall
2013), Pseudomonas spp. (Vogwill et al. 2014, 2016),
Mycobacterium smegmatis (Borrell et al. 2013), and Mtb
(Gagneux et al. 2006; Zaczek et al. 2009). In line with these
previous studies, we found that the OFX MIC and the
fitness effect conferred by a given gyrA mutation varied
significantly depending on the Mtb genetic background
they occur in (figs. 4 and 5A; supplementary table S6,
Supplementary Material online). These results suggest
that epistasis plays a role in determining the strain-
dependent OFX-R frequencies and mutational profiles
observed during our fluctuation analyses (figs. 3 and 5B).
The epistasis between the Mtb genetic background and
FQ-R mutations may have clinical consequences. A recent
study has shown that drug-susceptible Mtb strains with
higher MICs to INH and RIF were associated with increased
risk of relapse following first-line treatment (Colangeli et al.
2018). FQ-R gyrA mutations that confer higher MICs, such as
any gyrA mutation in codon D94 except for D94A, have also
been associated with poorer treatment outcomes in MDR-TB
patients (Rigouts et al. 2016; Farhat et al. 2017). Considering
our observation that the Mtb genetic background affected
both the OFX MICs and OFX-R mutational profiles (figs. 3 and
4; supplementary tables S4–S6, Supplementary Material
online), the genetic background may therefore contribute
to differences in patient treatment outcomes when using
FQs as first-line drugs.
Using publicly available genomic data from Mtb clinical
isolates, we observed significant lineage-dependent variation
in the frequency of and mutational profiles for FQ-R (fig. 6).
As expected, the vast majority of FQ-R mutations were ob-
served in gyrA (supplementary tables S10 and S11,
Supplementary Material online) (Takiff et al. 1994; Zhou
et al. 2000; Piton et al. 2010; Maruri et al. 2012; Aldred et al.
2016; Blower et al. 2016; Wollenberg et al. 2017). FQ-R was
also most frequent in L2 and L4. This was also as expected, as
strains from the L2 Beijing sublineage are known to associate
with MDR-TB (Borrell and Gagneux 2009; Fenner et al. 2012;
Merker et al. 2015; Wollenberg et al. 2017), while L4 strains are
the most prevalent globally, including in regions classified as
high burden for TB (Stucki et al. 2016; World Health
Organization 2017; Brynildsrud et al. 2018; Gagneux 2018).
Consequently, strains from L2 and L4 would be more exposed
to FQs, leading to the higher FQ-R frequencies observed in
these two lineages. Furthermore, we observed that more than
half of the variability in the clinical frequency of FQ-R gyrA
mutation events in L2 strains can be explained by how Mtb
evolves in vitro (fig. 7). However, the in vitro FQ-R evolution
could only account for 39% of the variability for the frequency
of FQ-R gyrA mutation events in clinical L4 strains. This sug-
gested that while the Mtb genetic background can influence
the evolution of FQ-R in the clinic, other factors (which may
be independent of the Mtb genetic background) likely played
strong roles as well. Epidemiological factors including socio-
economic disruptions, health system inefficiencies, and hu-
man behavior are well known risk factors for the emergence
and transmission of AMR in Mtb (Dalton et al. 2012; Merker
et al. 2015; Alvarez-Uria et al. 2016; Eldholm et al. 2016; Shah
et al. 2017). Meanwhile, biological factors not explored in this
study, such as antibiotic type and concentration (Zhou et al.
2000; Ford et al. 2013; Lindsey et al. 2013; McGrath et al. 2014;
Mustaev et al. 2014; Malik et al. 2016), pharmacodynamic and
pharmacokinetic features (Pienaar et al. 2017; Sarathy et al.
2018), and the selective pressure of the host immune system
(Handel et al. 2009), may also influence the evolution of FQ-R.
How the genetic background modulates FQ-R evolution
in the clinic may also differ between different bacterial
pathogens. In contrast to Mtb where DNA gyrase is the
sole target for FQs, Gram-negative bacteria such as E. coli
and Salmonella have two targets for FQs: DNA gyrase and
topoisomerase IV (Hooper 1999). In E. coli, the evolutionary
trajectory toward high-level FQ-R generally involves the
stepwise acquisition of FQ-R mutations in either DNA gyr-
ase or topoisomerase IV (Huseby et al. 2017). Therefore, the
genetic background of Gram-negative bacteria may modu-
late the phenotypes of FQ-R mutations not only in DNA
gyrase but in topoisomerase IV as well. Nevertheless, a re-
cent study has shown that a common FQ-R mutation in
Gram-negative bacteria, GyrA S83L, confers different phe-
notypes depending on whether it is present in E. coli or in
Salmonella (Apjok et al. 2019). This suggests that the genetic
background of Gram-negative bacteria may affect the evo-
lution of FQ-R in the clinic. This type of epistasis is also not
restricted to bacteria. The genetic background modulated
the phenotypes of AMR mutations in the protozoan
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parasite Leishmania donovani (Decuypere et al. 2012), and
the phenotypes of mutations in yeast when exposed to dif-
ferent environments, including antimicrobial exposure
(Mullis et al. 2018). Thus, while the mode of epistasis be-
tween the genetic background and the phenotypes of muta-
tions may differ in different organisms and environments,
published work and the results of our study provide com-
pelling evidence that this epistasis is a major factor in the
evolution of AMR in both prokaryotic and eukaryotic
organisms.
Our study is limited by the fact that our survey of clinical
FQ-R frequencies involved a genomic data set that was sam-
pled by convenience. This data set was used due to its public
availability, and may not be fully representative of FQ-R fre-
quencies in Mtb populations. We noted that lineage-specific
frequencies of FQ-R were likely biased due to the overrepre-
sentation L2 and L4 strains. Thus, to acquire a better under-
standing on which FQ-R mutations appeared and at what
frequency they occurred at in different Mtb lineages, either
more genomes from clinical isolates from other Mtb lineages
must be made available, or a population-based study must be
undertaken, preferably in a high-burden MDR-TB region.
Exposure to quinolones have been shown to lead to SOS
response-mediated mutagenesis, which can increase the rate
of AMR acquisition, including resistance to quinolones them-
selves (Cirz et al. 2005; Malik et al. 2010; Frenoy and
Bonhoeffer 2018). Therefore, the strain-dependent OFX-R ac-
quisition rates (fig. 1) may be due to strain-dependent differ-
ences in the magnitude of quinolone-induced mutagenesis.
We did not explicitly test for this possibility. However, phy-
logenetic SNPs present in SOS response-related genes may
lead to strain-dependent differences in quinolone-induced
mutagenesis, and we observed no such SNPs present across
our panel of drug-susceptible Mtb strains (supplementary
table S2, Supplementary Material online) (Borrell et al.
2019). Thus, we observed no genetic evidence for strain-
specific SOS response-mediated mutagenesis. Furthermore,
in E. coli, quinolone-induced quinolone-resistant mutations
may only be observed after 5 days of incubation with quino-
lones, which is equivalent to >220 generations for wild-type
E. coli (Cirz et al. 2005; Fujikawa and Morozumi 2005).
Meanwhile, our wild-type Mtb strains were incubated for
40 generations at most in the presence of OFX (see
Materials and Methods and supplementary table S7,
Supplementary Material online), making the likelihood of ob-
serving OFX-induced OFX-R mutants in our in vitro system
extremely low.
Another limitation of our study is that fluctuation analyses
only model AMR emergence. Long-term population dynam-
ics also play an important role in AMR evolution (zur Wiesch
et al. 2011; Lindsey et al. 2013; Huseby et al. 2017). For exam-
ple, population bottleneck events modulate AMR evolution
during serial transfer experiments (Comas et al. 2012; Barrick
and Lenski 2013; Vogwill et al. 2016; Huseby et al. 2017), and
have also been hypothesized to strongly influence Mtb evo-
lution in the clinic (Hershberg et al. 2008). Thus, modeling FQ-
R evolution in Mtb in epidemiological settings would benefit
from the use of some measure of long-term population
dynamics and between-host transmission. Nevertheless, the
fitness of AMR mutants is an important factor in determining
its evolutionary fate (zur Wiesch et al. 2011; Angst and Hall
2013; Barrick and Lenski 2013; Lindsey et al. 2013; Hughes and
Andersson 2017; Huseby et al. 2017) and its potential for
between-host transmission (Comas et al. 2012; de Vos et al.
2013). Considering that the Mtb genetic background modu-
lated the fitness effect of FQ-R mutations (fig. 5 and supple-
mentary table S7, Supplementary Material online), the
genetic background may modulate how likely FQ-R mutants
transmit between patients.
In conclusion, we illustrate how the genetic variation pre-
sent in natural populations ofMtb modulates FQ-R evolution.
Considering the nonrandom geographic distribution of dif-
ferent Mtb genetic variants (Comas et al. 2010; Gagneux
2018), our work suggests that there may be regional differ-
ences in the rate of FQ-R emergence and FQ-R prevalence
when using FQs as a first-line drug. We therefore highlight the
importance of standing genetic variation in determining how
FQ-R evolves in Mtb and, in general, how AMR evolves in
pathogens.
Materials and Methods
Collection of Drug-Susceptible Clinical Isolates of Mtb
Strains for In Vitro Studies
We used nine genetically distinct Mtb strains, with three
strains from each of the following Mtb lineages: Lineage 1
(L1; also known as the East-Africa and India Lineage),
Lineage 2 (L2; the East Asian Lineage), and Lineage 4 (L4;
the Euro-American Lineage) (Comas et al. 2010; Gagneux
2018). All strains were previously isolated from patients, fully
drug-susceptible, and previously characterized by Borrell et al.
(2019) (supplementary table S1, Supplementary Material
online).
Prior to all experimentation, starter cultures for each Mtb
strain were prepared by recovering a 20ll aliquot from frozen
stocks into a 10 ml volume of Middlebrook 7H9 broth (BD),
supplemented with an albumin (Fraction V, Roche), dextrose
(Sigma–Aldrich), catalase (Sigma–Aldrich), and 0.05% Tween
80 (AppliChem) (hereafter designated as 7H9 ADC). These
starter cultures were incubated until their optical density at
wavelength of 600 nm (OD600) was 0.50, and were then
used for in vitro assays.
Fluctuation Analyses
Fluctuation analyses were performed as described by Luria
and Delbru¨ck (1943). Briefly, an aliquot from the starter cul-
tures for each strain was used to inoculate 350 ml of 7H9 ADC
to have an initial bacterial density of 5,000 colony forming
units (CFU) per milliliter. This was immediately divided into
33 parallel cultures, each with 10 ml of culture volume ali-
quoted into individual 50 ml Falcon Conical Centrifuge Tubes
(Corning Inc.). The parallel cultures were incubated at 37 C
on standing racks, with resuspension by vortexing (Bio Vortex
V1, Biosan) every 24 h. Cultures were grown until an OD600 of
between 0.40 and 0.65. Once at this density, final cell counts
(Nt) from three randomly chosen parallel cultures were
Fluoroquinolone-Resistance in Mtb . doi:10.1093/molbev/msz214 MBE
203
D
ow
nloaded from
 https://academ
ic.oup.com
/m
be/article-abstract/37/1/195/5571370 by W
W
Z Bibliothek (O
effentliche Bibliotherk der U
niversitÃ¤t Basel) user on 12 February 2020
calculated by serial dilution and plating on Middlebrook 7H11
(BD), supplemented with oleic acid (AppliChem), albumin,
and catalase (hereafter referred to as 7H11 OADC). To calcu-
late the number of resistant colonies (r), the remaining 30
parallel cultures not used for Nt determination were pelleted
at 800g for 10 min at 4 C using the Allegra X-15R Benchtop
Centrifuge (Beckmann Coulter). The supernatants were dis-
carded, and the bacterial pellets resuspended in 300ll of 7H9
ADC. The resuspensions were spread on 7H11 OADC plates
supplemented with the relevant drug concentration (2, 4, or
8mg/ml of ofloxacin, or 100mg/ml STR; Sigma). Resistant col-
onies were observed and enumerated after 21–35 days of
incubation, depending on the Mtb strain. The frequency of
drug-resistant mutants per culture (r) was enumerated, and
the estimated number of drug-resistance mutations per cul-
ture (m) was estimated from the distribution of the r values
(rdist) using the Ma, Sarkar, Sandri-Maximum Likelihood
Estimator method (MSS-MLE) (Rosche and Foster 2000).
Values of r that were >300 were simply given a value of
300, as this would not change the precision of the calculated
m value using the MSS-MLE method (Rosche and Foster
2000). The MSS-MLE method is also only valid for a range
ofm values between 0.3 and 20 (Rosche and Foster 2000). The
frequency of drug-resistance mutations acquired per cell (F)
per strain was then calculated by dividing the calculated m
values by their respective Nt values. The 95% confidence
intervals for each F were calculated as previously described
by Rosche and Foster (2000). Hypotheses testing for signifi-
cant differences between the rdist between strains for the
fluctuation analyses at 4mg/ml of OFX (fig. 1A) and at
100mg/ml of STR (fig. 2) were performed using the
Kruskal–Wallis test; significant differences in the rdist between
strains in the fluctuation analyses at 2 and 8mg/ml (fig. 1B)
were tested for using the Wilcoxon rank-sum test. Statistical
analyses were performed using the R statistical software
(v.3.5.1) (R Core Team 2018).
Determining the Mutational Profile for OFX-R In Vitro
From the parallel cultures plated on 4mg/ml of OFX (fig. 1A),
up to 120 resistant colonies per strain (at least 1 colony per
plated parallel culture if colonies were present, to a maximum
of 6) were transferred into 100ll of sterile deionized H2O
placed in Falcon 96-well Clear Microplate (Corning Inc.). The
bacterial suspensions were then heat-inactivated at 95 C for
1 h, and used as PCR templates to amplify the QRDR in gyrA
and gyrB using primers designed by Feuerriegel et al. (2009).
PCR products were sent to Macrogen, Inc. or Microsynth AG
for Sanger sequencing, and QRDR mutations were deter-
mined by aligning the PCR product sequences against the
H37Rv reference sequence (Cole et al. 1998). Sequence align-
ments were performed using the Staden Package (Staden
1996), while the amino acid substitutions identification
were performed using the Molecular Evolutionary Genetics
Analysis Version 6.0 package (Tamura et al. 2013). Fisher’s
exact test was used to test for significant differences between
the strains’ mutational profiles for OFX-R. Data analyses were
performed using the R statistical software (v.3.5.1) (R Core
Team 2018), and figures were produced using the ggplot2
package (Wickham, 2016).
Isolation of Spontaneous Ofloxacin-Resistant Mutants
Spontaneous OFX-resistant mutants were isolated from
strains belonging one of three genetic backgrounds: N0157
(L1, Manila sublineage), N1283 (L4, Ural sublineage), and
N0145 (L2, Beijing sublineage) (Borrell et al. 2019). To begin,
we transferred 50ll of starter cultures for each strain into
separate culture tubes containing 10 ml of fresh 7H9 ADC.
Cultures were incubated at 37 C until OD600 of 0.80, and
pelleted at 800g for 5 min at 4 C. The supernatant was
discarded, and the pellet resuspended in 300ll of 7H9 ADC.
The resuspension was plated on 7H11 OADC (BD) supple-
mented with 2lg/ml of OFX, and incubated until resistant
colonies appeared (14–21 days). Resistant colonies were
picked and resuspended in fresh 10 ml 7H9 ADC, and incu-
bated at 37 C. Once the culture reached early stationary
phase, two aliquots were prepared. The first aliquot was
heat-inactivated at 95 C for 1 h, and the gyrA mutation
identified by PCR and Sanger sequencing, as described in
the mutational profile for OFX-R assay. If the first aliquot
harbored one of four OFX-R gyrA mutations (GyrAD94G,
GyrAD94N, GyrAA90V, or GyrAG88C), the second aliquot was
stored in 80 C for future use.
Prior to further experimentation with the spontane-
ously OFX-resistant mutant strains, starter cultures
were prepared in the same manner as for the drug-
susceptible strains.
Drug Susceptibility Assay
We determined the OFX-susceptibility levels of our sponta-
neous OFX-resistant mutants and their respective drug-
susceptible ancestors by performing the colorimetric, micro-
titer plate-based Alamar Blue assay (Franzblau et al. 1998).
Briefly, we used a Falcon 96-well Clear Microplate, featuring a
serial 2-fold dilution of OFX. For drug-susceptible strains, a
range of OFX concentration from 15 to 0.058lg/ml was used.
Meanwhile, for OFX-resistant strains, a range of 60–0.234lg/
ml was used. Each well was inoculated with a 10ll volume of
starter culture to have a final inoculum of5 106 CFU/ml.
The plates were incubated at 37 C for 10 days. Following
incubation, 10ll of Resazurin (Sigma) were added to each
well, and the plates were incubated for another 24 h at 37 C.
After this incubation period, plates were inactivated by add-
ing 100ll of 4% formaldehyde to every well. Measurement of
fluorescence produced by viable cells was performed on
SpectraMAX GeminiXPS Microplate Reader (Molecular
Devices). The excitation wavelength was set at 536 nm, and
the emission wavelength at 588 nm was measured. Minimum
inhibitory concentration (MIC) for OFX was determined by
first fitting a Hill curve to the distribution of fluorescence, and
then defining the MIC as the lowest OFX concentration
where the fitted Hill curve showed a 95% reduction in fluo-
rescence. Two sets of experiments were performed for every
strain, with three technical replicates per experiment.
Analyses of MIC data were performed and figures created
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using the numpy, scipy, pandas, and matplotlib modules for
the Python programming language.
Cell Growth Assay
We set up three or four 1,000 ml roller bottles with 90 ml of
7H9 ADC and 10 ml borosilicate beads. Each bottle was inoc-
ulated with a volume of starter cultures so that the initial
bacterial density was at an OD600 of 5 107. The inoculated
bottles were then placed in a roller incubator set to 37 C, and
incubated for 12–18 days with continuous rolling. OD600
measurements were taken once or twice every 24 h. Two
independent experiments in either triplicates or quadrupli-
cates were performed per strain.
We defined the exponential phase as the bacterial growth
phase where we observed a log2-linear relationship between
OD600 and time; specifically, we used a Pearson’s R
2 value 
0.98 as the threshold. The growth rate of a particular strain
was then defined as the slope of the linear regression model.
The relative fitness of a given spontaneous OFX-R mutant
was defined by taking the growth rate of the OFX-resistant
mutant strain and dividing it by the growth rate of its respec-
tive drug-susceptible ancestor. Linear regression models for
the cell growth assays data were performed using the numpy,
scipy, pandas, and matplotlib modules for the Python pro-
gramming language, as well as the R statistical software
(v.3.5.1) and the ggplot2 package (Wickham, 2016; R Core
Team 2018).
Surveying the FQ-R Profile from Publicly AvailableMtb
Genomes
We screened public databases to download global represen-
tatives of Mtb genomes, as described by Menardo et al.
(2018). We selected genomes that were classified as MDR-
TB based on the presence of both INH-R and RIF-R muta-
tions. This provided a data set of 3,450 genomes with
confirmed MDR-TB; their accession numbers are reported
in supplementary table S8, Supplementary Material online.
These MDR-TB genomes were then screened for the presence
of FQ-R mutations, and we identified 854 genomes that were
classified as FQ-R.
The INH-R, RIF-R, and FQ-R mutations used for screening
are the same mutations used by Payne et al. (2019), and are
listed in supplementary table S13, Supplementary Material
online. A drug-resistance mutation was defined as “fixed” in
the population when it reached a frequency of 90%.
Meanwhile, a drug-resistance mutation was considered
“variable” in the population when its frequency was between
10% and 90%; thus, multiple drug-resistance mutations may
be present in the genomic data from a single Mtb clinical
isolate.
Defining Transmission Clusters and Determining the
Frequency of FQ-R gyrA Mutation Events
To define transmission clusters, the differences in the number
of SNPs were used as a measure of genetic distance between
two Mtb genomes. Using the haplotypes package (v.1.0) for
the R statistical software (v.3.5.1) (R Core Team 2018), a ge-
netic distance matrix was then inferred for the 3,450 MDR-TB
genomes. Insertions/deletions were considered missing data.
Agglomerative clustering was performed using the agnes
function from the cluster package (v.2.0.6) for the R statistical
software (R Core Team 2018). A conservative threshold of 12
SNPs average distance was used to define likely patient-to-
patient transmission (Walker et al. 2013), and the tree was cut
at a height of 12 SNPs using the hclust function. All resulting
transmission clusters, with a minimum size of two clustered
genomes, were used for further analysis. For every transmis-
sion cluster, each unique and fixed FQ-R gyrA mutation was
treated as an independent mutation event. Fixed FQ-R gyrA
mutations in nonclustered Mtb genomes were also treated as
an independent mutation event. Figures were produced using
the ggplot2 package (Wickham, 2016).
Supplementary Material
Supplementary data are available at Molecular Biology and
Evolution online.
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